Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 4-part Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of M254 in Healthy Volunteers and in Patients With Immune Thrombocytopenic Purpura

NCT03866577 is registered in ClinicalTrials.gov with Momenta Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03866577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03866577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 4-part Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of M254 in Healthy Volunteers and in Patients With Immune Thrombocytopenic Purpura
Lead sponsor
Momenta Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
December 21, 2018
Completion date
June 9, 2021
Enrollment
50 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenic purpura (itp)